<DOC>
	<DOC>NCT00163462</DOC>
	<brief_summary>The aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function, symptoms, and use of rescue medication in children with persistent asthma. Ciclesonide will be inhaled once daily, using one of the two dose levels; fluticasone propionate will be inhaled at one dose level twice daily. The study duration consists of a baseline period (2 to 4 weeks) and a treatment period (12 weeks). The study will provide further data on safety and tolerability of ciclesonide.</brief_summary>
	<brief_title>Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Main History of persistent bronchial asthma for at least 6 months FEV1 5090% of predicted Main Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function Respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study History of lifethreatening asthma Premature birth Current smoking Smoking history with either equal or more than 10 packyears Pregnancy Intention to become pregnant during the course of the study Breast feeding Lack of safe contraception</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>Child</keyword>
	<keyword>Fluticasone propionate</keyword>
	<keyword>Pediatric</keyword>
</DOC>